Full-Stack Developer - Multiple Teams
About the job
- A higher-education qualification in computing at bac +3 level or above is required.
- Two to five years of web development experience are required, with good command of TypeScript and React; Next.js is appreciated.
- Solid knowledge of REST API architecture, Node.js, Express, relational databases, and object-relational mapping is required.
- Proficiency in Git and associated best practices is required.
- Fluent French and basic English are required.
- Teamwork, rigor, and organizational skills are required.
- Analyze and develop new features using React, Next.js, TypeScript, and Express.
- Participate in technical design and architecture decisions in collaboration with the internal team and service providers.
- Manage day-to-day application maintenance.
- Provide application support and helpdesk assistance.
- Write procedures and keep documentation up to date.
- Experience in the medical field or with compliance requirements such as HDS and GDPR is an advantage.
About the company
Advanced Biological Laboratories provides software, assays, and IT solutions for infectious disease diagnostics and clinical genotyping. It supports molecular detection, sequencing-based genotyping, and data analysis for pathogens such as HIV, SARS-CoV-2, HBV, HCV, and tuberculosis, compatible with Sanger and Next Generation Sequencing. The company earns recurring revenue by offering end-to-end solutions for labs and researchers, including CRO services and assay manufacturing through acquisitions. Its aim is to deliver integrated tools that streamline detection, drug-resistance analysis, and data-driven patient management in infectious diseases.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Luxembourg, Luxembourg
Founded
2000
Simplify's Take
What believers are saying
- ABL Diagnostics posted H1 2026 revenue of €5.415 million, up 90%.
- July 2026 UltraGene Viral Meningitis and Respiratory Pathogens 21 expanded the menu.
- ABL selected by Évry Commercial Court on July 22, 2026, to acquire TEXCELL operations.
What critics are saying
- ABL abandoned ProPhase Labs reverse merger on February 19, 2026, signaling deal fragility.
- Main shareholder sold ABL Diagnostics blocks again on June 5 and July 22, 2026.
- IVDR deadlines threaten legacy UltraGene and DeepChek products if certification slips past 2028-2029.
What makes Advanced Biological Laboratories unique
- ABL controls assays, sequencing software, and manufacturing across infectious-disease workflows.
- Its Fast Track Diagnostics rights and DeepChek portfolio create recurring laboratory revenue.
- ABL uses CE-IVD devices and ISO 13485 manufacturing to ship globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Flexible Work Hours
- Professional Development Budget